FY2028 EPS Estimates for Passage Bio, Inc. (NASDAQ:PASG) fell with Wedbush

Passage Bio, Inc. (NASDAQ: PASG – Free Report ) – Analysts at Wedbush lowered their FY2028 EPS estimates for shares of Passage Bio in a research report issued on Thursday, August 8th. Wedbush analyst L. Chico now expects that the company will post earnings of $0.02 per share for the year, down from their prior estimate of $0.05. The consensus estimate for Passage Bio’s current earnings for the full year is ($1.06) per share.

Passage Bio (NASDAQ: PASG – Get Your Free Report ) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05.

Separately, Canaccord Genuity Group decreased their price objective on shares of Passage Bio from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Wednesday, May 15th.

Check out our latest review of Passage Bio

Passage Bio Stock performance

Shares of Passage Bio stock traded down $0.05 during trading hours on Friday, reaching $0.73. 1,233,660 shares of the stock exchanged hands, compared to its average volume of 276,982. The stock has a market cap of $45.11 million, a P/E ratio of -0.48 and a beta of 1.20. Passage Bio has a 52 week low of $0.58 and a 52 week high of $1.79. The company’s 50-day moving average is $0.95 and its 200-day moving average is $1.17.

Hedge funds weigh in on Passage Bio

Institutional investors and hedge funds have recently made changes to their positions in the stock. Pale Fire Capital SE increased its stake in Passage Bio by 489.1% during the 4th quarter. Pale Fire Capital SE now owns 581,257 shares of the company’s stock worth $587,000 after buying an additional 482,595 shares during that period. Acadian Asset Management LLC grew its stake in Passage Bio by 59.0% in the first quarter. Acadian Asset Management LLC now owns 961,271 shares of the company’s stock worth $1,296,000 after acquiring an additional 356,593 shares during the period. Vanguard Group Inc. raised its stake in shares of Passage Bio by 2.6% in the first quarter. Vanguard Group Inc. now owns 2,071,538 shares of the company’s stock worth $2,797,000 after purchasing an additional 52,656 shares during the period. Lynx1 Capital Management LP grew its stake in Passage Bio by 1,178.1% in the first quarter. Lynx1 Capital Management LP now owns 4,845,871 shares of the company’s stock worth $6,542,000 after buying an additional 4,466,712 shares during the period. Finally, Affinity Asset Advisors LLC purchased a new position in shares of Passage Bio in the first quarter worth $357,000. 53.48% of shares are owned by institutional investors and hedge funds.

Passage Bio company profile

(Get a free report)

Passage Bio, Inc, a gene medicine company, develops gene therapies for diseases of the central nervous system. She develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and progranulin (PGRN) encoding gene for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.

Further reading

Get news and reviews for Passage Bio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Passage Bio and related companies with MarketBeat.com’s FREE daily email newsletter.